Moderna : 2021: a transformative financial year for the group
>2021 guidance well ahead of expectations - Yesterday afternoon, Moderna published its 2020 results. They were well above expectations on sales but due to hefty R&D costs at the end of the year, they are below expectations at the earnings level. As previously announced, the company confirms its cash position at $ 5.25bn at the end of 2020. However, this year-end is only anecdotal, as the objective is still obviously 2021, which is a transformative year for the group....Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.